Southeastern Research Center | Winston-Salem, NC
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
Study details include:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
300 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Trial Transparency email recommended (Toll free for US & Canada)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal